Molecular basis off hurthle cell XXXX .

@entity3557 @entity8958 @entity1637 @entity146 @entity5 @entity1358 @entity10307 @entity10731 @entity3 @entity652 @entity259 @entity2750
Among @entity259 , @entity1637 ( @entity1637 ) have traditionally been a distinct diagnostic category. Hurthle cell @entity652 are encapsulated follicular lesions with benign behavior. @entity1358 exhibit unequivocal capsular and/or vascular invasion; they are @entity146 with a poor prognosis. Recently, Hurthle cell @entity3557 ( @entity3557 ) have been identified on morphological grounds. We hypothesize that a subset of @entity1637 represent PTC with clinical, histological, and immunohistochemical features based on specific molecular events. @entity8958 /PTC gene rearrangements give rise to novel oncogenes that are unique to PTC. We studied a group (n = 50) of @entity1637 for @entity8958 /PTC gene rearrangements. @entity5 were examined for papillary differentiation by light microscopic evaluation of nuclear features, by RT-PCR for @entity8958 /PTC gene rearrangements, and by immunohistochemistry for @entity8958 . Among 24 noninvasive @entity5 , 13 contained @entity10731 for @entity8958 / @entity2750 , -2, or -3, and 9 of these were immunoreactive for @entity8958 . Among 19 @entity1358 , 15 had focal @entity10307 with grooves and/or inclusions; expressed transcripts of @entity8958 / @entity2750 , -2, or-3; and exhibited @entity8958 positivity. @entity5 with @entity8958 /PTC gene rearrangements tended to have lymph node @entity3 rather than hematogenous spread. Our results indicate that a subset of @entity1637 exhibit features of PTC that are attributable to specific gene rearrangements, resulting in expression of @entity8958 /PTC oncogenes. These data support subclassification of @entity1637 into three groups: Hurthle cell @entity652 , @entity1358 , and Hurthle cell PTC.
